evipedia.ai
← Back

Ivermectin to Treat Cancer

Evidence Review created on 09/27/2026 using AI4L / Opus 5.5

Also known as: Stromectol, Mectizan, Soolantra, Sklice, Ivomec, MK-933

Motivation

Ivermectin is an inexpensive antiparasitic medication, given as oral tablets, that has treated river blindness and other worm infections in hundreds of millions of people. Laboratory research suggests it may also slow cancer cells by interfering with several of the growth signals they depend on, and this has drawn intense interest from people looking for additional ways to fight their disease.

Interest grew sharply after the coronavirus pandemic made the drug widely known. Practitioner networks, online patient communities and new state laws in America have since made it easier to obtain, and many people with cancer now take it alongside, or sometimes instead of, standard treatment. The laboratory and animal literature is large, and the same data have drawn strongly opposed readings.

This review examines the laboratory and human evidence on whether ivermectin controls cancer, the risks of the higher and longer dosing used for this purpose, its interactions with cancer medications, and how practitioners dose and monitor it. It is written for people with cancer who want to weigh this option with the full evidence in view.

Benefits - Risks - Protocol - Conclusion

Five items presenting the laboratory case for repurposing, a clinical skeptic’s review, practitioner dosing experience, a critique of practitioner networks and a patient-facing summary.

No directly relevant content was found from Peter Attia, Rhonda Patrick, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io: their sites either return no ivermectin content or discuss ivermectin only for COVID-19, not for cancer.

Grokipedia

Ivermectin

A broad encyclopedia entry whose sections on investigational anticancer potential and unapproved cancer use summarize laboratory findings, the breast cancer combination trial and regulatory positions alongside toxicity warnings.

Examine

No Examine article on ivermectin exists. Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on ivermectin exists; its search returns only two brief 2021 clinical updates on ivermectin for COVID-19. ConsumerLab does not typically cover prescription medications.

Systematic Reviews

One systematic review addresses the principal risk of the higher doses used in cancer; none addresses ivermectin’s effect on cancer itself.

No systematic reviews or meta-analyses for ivermectin as a cancer treatment were found on PubMed as of September 27, 2026, so the claimed anticancer effect is unrepresented in this section.

Mechanism of Action

Ivermectin kills parasites by locking open chloride channels found in worm nerves and muscles but not in humans. Proposed anticancer actions, all from cell and animal studies, include:

  • PAK1 and Akt/mTOR: ivermectin promotes breakdown of PAK1 (a growth-signaling enzyme), shutting down Akt/mTOR (a cell growth and survival switch) and triggering growth-halting autophagy (cellular self-digestion) (Dou et al., 2016).
  • WNT-TCF signaling (a developmental growth pathway): blocked in human cancer cells and xenografts (human tumors grown in mice) (Melotti et al., 2014).
  • Chloride influx and oxidative stress: leukemia cells die preferentially over normal blood cells (Sharmeen et al., 2010).
  • P2X4/P2X7 receptors (sensors of ATP, the cell’s energy molecule): inflammatory cell death that may attract T cells (immune cells that kill abnormal cells) (Draganov et al., 2015).

Critics argue these effects may be laboratory artifacts: most need 5–20 µM (micromolar, a concentration unit) (Hashimoto et al., 2009), above blood levels reached even at ten times the approved dose (Guzzo et al., 2002), and cell killing vanished once precipitates (undissolved drug particles) were filtered out (Qabbus et al., 2022). Supporters report effects at 5 µM and consider this reachable (Juarez et al., 2020).

Ivermectin has a half-life of about 18 hours, low selectivity, high fat solubility with wide distribution into fat and liver, and exclusion from the brain by P-glycoprotein (a drug-exporting pump). It is metabolized mainly by CYP3A4 (the liver enzyme that clears many drugs) and excreted in feces (González Canga et al., 2008).

Historical Context & Evolution

Ivermectin derives from avermectins, made by the soil bacterium Streptomyces avermitilis, which Satoshi Ōmura isolated and William Campbell’s Merck team developed in the 1970s. It reached livestock in 1981 and human use in 1987 against onchocerciasis (river blindness, a parasitic eye and skin disease), with Merck donating it for mass treatment. The US Food and Drug Administration (FDA, the US drug regulator) approved it in 1996 for onchocerciasis and strongyloidiasis (a threadworm gut infection), and the discovery earned the 2015 Nobel Prize (Tang et al., 2021).

Cancer interest began with 1990s reports of reversed multidrug resistance in cancer cells (Pouliot et al., 1997), then grew through repurposing screens: it killed leukemia cells (Sharmeen et al., 2010) and slowed WNT-driven tumors in mice (Melotti et al., 2014). A 2018 review argued these findings justified rapid clinical trials (Juarez et al., 2018).

During the COVID-19 pandemic, large trials found no benefit for that infection but added safety data at 600 µg/kg for six days (Naggie et al., 2023). Attention then shifted to cancer through practitioner networks, social media and state laws (including Tennessee, Arkansas, Idaho and Louisiana) permitting sale without prescription. The first human combination trial is co-sponsored by Agenus, the partner antibody’s maker (Yuan et al., 2025), and a 2026 cohort reporting benefit comes from authors affiliated with the McCullough Foundation and The Wellness Company, a commercial telehealth provider (Hulscher et al., 2026). Against these stand a journal expression of concern about a key mouse study and mounting toxicity reports.

Expected Benefits

High 🟩 🟩 🟩

Cure of Threadworm Infection Before Immune-Suppressing Cancer Treatment ⭕️ Not Central to Treat Cancer

Strongyloidiasis can turn into fatal hyperinfection (overwhelming spread) when chemotherapy or corticosteroids (steroid anti-inflammatory drugs such as prednisone) suppress immunity, and ivermectin is its first-line treatment. A Cochrane review of seven randomized controlled trials (1,147 participants) found higher cure rates than albendazole with similar tolerability (Henriquez-Camacho et al., 2016). This bears on infection safety for people with cancer who have lived in tropical or subtropical regions, not on tumor control.

Magnitude: Parasitological cure was 1.79 times as likely as with albendazole (relative risk, the ratio of event rates between groups, 1.79; 95% confidence interval, the plausible range of the true value, 1.55–2.08).

Medium 🟩 🟩

No benefit reaches Medium: the human cancer data consist of one small uncontrolled dose-finding trial, a self-reported cohort without a comparison group, and case reports.

Low 🟩

Tumor Control in Advanced Cancer ⚠️ Conflicted

Ivermectin plus balstilimab, a checkpoint inhibitor (a drug that releases immune brakes), produced one response in eight women with triple-negative (hormone-insensitive) breast cancer (Yuan et al., 2025). In an ivermectin-mebendazole telemedicine cohort, regression was self-reported, without imaging or controls (Hulscher et al., 2026). Net reading: tumor control remains unproven.

Magnitude: In the trial, 1 of 8 evaluable patients (12.5%) had a partial response, 6 progressed, and median progression-free survival (time until the cancer grew or the patient died) was 2.5 months; in the cohort, 48.4% of 122 respondents reported regression or no evidence of disease and 15.6% reported progression.

Symptom Relief in Advanced Cancer

Three case reports describe marked symptom relief after ivermectin was added to dichloroacetate and omeprazole (Ishiguro et al., 2022). In an Ecuadorian survey, cancer patients using ivermectin reported feeling better after several doses (Jiménez-Gaona et al., 2023). Both are uncontrolled, and ivermectin’s share of any effect cannot be separated.

Magnitude: Not quantified in available studies. Only case reports and an interview survey exist, and none used a validated symptom scale.

Speculative 🟨

Immune Activation Against “Cold” Tumors

In mice, ivermectin drew T cells into breast tumors and boosted checkpoint antibodies (Draganov et al., 2021). Basis is animal-only; a 2026 journal expression of concern flags duplicated images.

Reversal of Chemotherapy Resistance

Ivermectin restored drug sensitivity in resistant cancer cells and mouse tumors, partly by reducing drug-exporting pumps (Jiang et al., 2019; Nappi et al., 2020). Evidence is from cell and animal studies only.

Suppression of Cancer Stem-Like Cells

Ivermectin preferentially inhibited breast cancer cells with self-renewing, stem-like traits thought to drive relapse (Dominguez-Gomez et al., 2018). Evidence is from cell cultures only.

Slowing of Metastasis and Tumor Blood-Vessel Growth

Ivermectin reduced cell migration, metastasis and new blood-vessel formation in cell and mouse models (Liu et al., 2016; Jiang et al., 2022). Basis is mechanistic; no human data exist.

Benefit-Modifying Factors

  • Tumor biology: Cancers dependent on WNT-TCF or YAP1 (a growth-promoting protein) signaling were most sensitive in laboratory work (Nambara et al., 2017); no tumor test predicts human response.
  • Drug-handling gene variants: Variants in CYP3A4, CYP3A5 (a related drug-clearing enzyme) and ABCB1 (the gene encoding P-glycoprotein) may alter blood levels and thus any concentration-dependent effect; no study links them to cancer outcomes.
  • Baseline biomarkers: Tumor PD-L1 (an immune-dampening protein on tumor cells) status is used to select patients in the combination trial; baseline tumor markers and imaging are the only way to judge change.
  • Sex: No sex-based differences in benefit have been studied; breast and ovarian cancer cell lines were among the most sensitive in laboratory screens (Juarez et al., 2020), a tumor-type rather than a sex effect.
  • Pre-existing conditions: Brain tumors are unlikely to benefit because P-glycoprotein keeps ivermectin out of the brain (Tang et al., 2021); people with threadworm infection gain a clear, separate benefit.
  • Age: The largest human cohort had a mean age of 67 (Hulscher et al., 2026); no age-stratified outcomes exist, and multiple medications in older adults narrow the margin for higher doses.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: placebo-controlled trials at up to ten times the approved dose show adverse-event rates close to placebo (Guzzo et al., 2002), and serious harms are documented only in observational cohorts, case series and poison-center reports, not in replicated trials.

Medium 🟥 🟥

Brain and Nerve Toxicity at High or Accumulated Doses

When doses are large, accumulated, or combined with drugs that block P-glycoprotein, ivermectin enters the brain and enhances GABA (the brain’s main calming messenger) signaling, causing confusion, ataxia (loss of coordination), seizures or coma. An Oregon poison-center series and a global adverse-reaction database review document such cases, mostly after veterinary products or high self-dosing (Temple et al., 2021; Chandler, 2018). A 73-year-old with metastatic breast cancer needed ventilation after self-dosing (Saperstein et al., 2026). Recovery is usually complete within days.

Magnitude: 6 of 21 poison-center exposures (29%) required hospitalization, 4 in intensive care, with no deaths; incidence per treated person is unknown.

Severe Reactions in People With Heavy Loa loa Infection

Loiasis (African eye-worm infection) with very high counts of microfilariae (larval worms in blood) can trigger encephalopathy (brain dysfunction) after ivermectin. A Cameroon study of 17,877 treated people defined the risk thresholds (Gardon et al., 1997). It concerns only people who have lived in West or Central Africa.

Magnitude: 20 serious reactions (0.11%) plus 2 comas among 17,877 treated; the odds ratio (how many times higher the odds are) for serious reactions exceeded 1,000 above 50,000 microfilariae/mL.

Low 🟥

Mild Digestive, Visual and Skin Side Effects ⚠️ Conflicted

Nausea, diarrhea, dizziness, blurred vision and rash occur at higher doses. Excess events at 600 µg/kg arose in malaria patients on antimalarials (Smit et al., 2018); healthy volunteers and COVID-19 outpatients showed placebo-like rates (Guzzo et al., 2002; Naggie et al., 2023). Net reading: mild effects affect a minority.

Magnitude: Treatment-related adverse events in 11% at 600 µg/kg daily for three days versus 0% on placebo; 25.4% reported side effects in the 122-person cancer cohort (Hulscher et al., 2026).

Forgoing or Delaying Effective Cancer Treatment

Using unproven therapy instead of standard treatment carries the largest potential harm. Among people with curable cancers, alternative medicine alone was linked to higher death rates (Johnson et al., 2018), driven by refusal of standard care (Johnson et al., 2018). Data are indirect, not ivermectin-specific.

Magnitude: Hazard ratio (the relative rate of death over time) 2.50 (95% confidence interval 1.88–3.27) for alternative medicine alone versus standard treatment.

Drug-Induced Liver Injury

Ivermectin has caused hepatitis weeks after dosing in isolated reports (Veit et al., 2006; Sonderup et al., 2023). A man with prostate cancer taking veterinary ivermectin and fenbendazole developed severe injury that resolved after stopping (Powderly et al., 2026). The mechanism is presumed to be an unpredictable individual reaction.

Magnitude: Not quantified in available studies. Only isolated case reports exist, so no incidence can be estimated.

Severe Skin Reactions

Toxic epidermal necrolysis (life-threatening skin peeling) has been reported after ivermectin (Seegobin et al., 2018). It is immune-mediated and very rare.

Magnitude: Not quantified in available studies. Only single case reports exist, so no incidence can be estimated.

Speculative 🟨

Weaker Immunotherapy Response Through Gut Bacteria Disruption

Ivermectin’s antimicrobial activity could disturb gut bacteria that support checkpoint-inhibitor responses, a concern motivating the ICONIC trial. Basis is mechanistic only.

Higher Chemotherapy Toxicity Through Pump Inhibition

Ivermectin lowered P-glycoprotein in resistant cancer cells (Jiang et al., 2019); similar effects in normal tissues could raise exposure to pump-dependent chemotherapy such as paclitaxel or doxorubicin. Basis is mechanistic only.

Risk-Modifying Factors

  • ABCB1 loss-of-function variants: A patient carrying nonsense (protein-truncating) ABCB1 mutations developed serious neurotoxicity (brain and nerve toxicity) after ivermectin (Baudou et al., 2020); such carriers are rare but unidentifiable without testing.
  • Baseline liver function: Elevated liver enzymes or cirrhosis slow clearance and complicate recognition of drug-induced liver injury.
  • Baseline Loa loa load: Encephalopathy risk rises above 8,000 microfilariae/mL and becomes very high above 50,000/mL (Gardon et al., 1997).
  • Sex and pregnancy: No sex-specific toxicity differences are documented; pregnancy safety data are limited and inconclusive (Nicolas et al., 2020).
  • Older age: Poison-center patients had a median age of 64 (Temple et al., 2021); older adults take more interacting drugs.
  • Co-medications: Strong CYP3A4 or P-glycoprotein inhibitors, including some oral cancer drugs, raise ivermectin exposure (Gilene et al., 2025).
  • Brain involvement: Brain metastases, recent brain radiation or meningitis may weaken the blood-brain barrier and increase brain exposure; this is mechanistic reasoning.
  • Low body weight: Fixed-strength capsules deliver a higher mg/kg dose to smaller patients.

Key Interactions & Contraindications

  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): Caution. Raise ivermectin levels, increasing neurotoxicity risk. Avoiding the combination, or using the lowest dose with close symptom checks, limits this risk.
  • P-glycoprotein inhibitors (verapamil, amiodarone, cyclosporine, quinidine): Caution. Increase brain entry, risking confusion and ataxia. Avoiding the combination or reducing the ivermectin dose limits this risk.
  • Oral kinase inhibitors (targeted cancer drugs blocking growth enzymes; regorafenib, sorafenib): Caution. Severe neurotoxicity was reported with regorafenib (Gilene et al., 2025). Review by an oncologist and pharmacist before combining identifies this risk.
  • Warfarin (a blood thinner): Monitor. Rising INR (international normalized ratio, a clotting-time measure) and bleeding were reported (Gilbert & Slechta, 2018). An INR check 3–7 days after starting or changing ivermectin detects this interaction.
  • CYP3A4 inducers (rifampin, carbamazepine, phenytoin): Monitor. Lower ivermectin levels, reducing any effect; keeping them unchanged during a course keeps levels stable.
  • Benzodiazepines (anti-anxiety sedatives such as lorazepam) and barbiturates (older sedatives such as phenobarbital): Caution. Additive sedation and confusion through shared calming-messenger pathways, greatest with high-dose ivermectin; avoiding the combination or lowering the ivermectin dose limits this risk.
  • Over-the-counter sedating antihistamines (diphenhydramine, doxylamine) and alcohol: Caution. Additive drowsiness and unsteadiness; alcohol raised ivermectin blood levels in one study (Shu et al., 2000). Avoiding them during higher-dose courses limits this risk.
  • Grapefruit juice (a CYP3A4 inhibitor): Monitor. May modestly raise ivermectin levels and side-effect risk; consistent intake keeps levels predictable.
  • Supplements inhibiting CYP3A4 or P-glycoprotein (piperine, curcumin, quercetin, green tea extract): Monitor. Often stacked in repurposed-drug protocols, adding to ivermectin exposure; introducing one at a time makes any reaction traceable.
  • St. John’s wort (a CYP3A4 inducer): Monitor. Lowers ivermectin levels, weakening any effect; not combining them preserves ivermectin levels.
  • Sedating supplements (valerian, kava, high-dose melatonin): Caution. Additive central nervous system sedation, greatest at bedtime with higher ivermectin doses; pausing them during higher-dose courses limits this risk.
  • Other antiparasitic drugs (mebendazole, fenbendazole): Monitor. Severe liver injury followed veterinary fenbendazole plus ivermectin (Powderly et al., 2026); liver tests every 2–4 weeks initially detect injury early.
  • Checkpoint inhibitors (pembrolizumab, balstilimab): Monitor. No treatment-related serious adverse events occurred in the first 9 Cedars-Sinai trial patients, as summarized in the ICONIC trial record, but a weaker immune response through gut-bacteria disruption is untested. Trial settings or oncologist oversight allow this to be tracked.
  • High-fat meals: Monitor. Raise absorption 2.6-fold (Guzzo et al., 2002); taking ivermectin the same way relative to meals each day keeps exposure consistent.

Populations who should avoid Ivermectin:

  • People with Loa loa infection above 8,000 microfilariae/mL (highest danger above 50,000/mL)
  • Pregnant people, especially in the first trimester, and breastfeeding people
  • Carriers of ABCB1 loss-of-function variants or anyone with prior ivermectin neurotoxicity
  • People with severe liver impairment (Child-Pugh class C, the most severe liver-disease category)
  • Children weighing less than 15 kg
  • People taking strong CYP3A4 or P-glycoprotein inhibitors that cannot be stopped
  • People with active central nervous system disease that disrupts the blood-brain barrier (e.g., meningitis)

Risk Mitigation Strategies

  • Pharmacy-grade products only: Weight-based human tablets or verified compounded capsules, never veterinary pastes or pour-ons, prevent the dosing errors behind most poison-center neurotoxicity cases.
  • Low start, slow titration: Starting near 0.2–0.3 mg/kg daily, increasing no faster than every 2–4 weeks and staying at or below 1 mg/kg limits neurotoxicity.
  • Symptom stop rule: Holding ivermectin for blurred vision, unsteadiness, confusion or unusual sleepiness, then restarting 25–50% lower after resolution, prevents progression to seizures or coma.
  • Interaction screen: A pharmacist review of CYP3A4 and P-glycoprotein inhibitors, warfarin and oral cancer drugs before starting and with each new prescription reduces interaction-driven neurotoxicity and bleeding.
  • Liver tests: ALT (alanine aminotransferase, a liver-cell enzyme) and bilirubin at baseline, at 4 weeks, then every 2–3 months, stopping if ALT exceeds 3 times the upper limit, prevents progressive liver injury.
  • Keep standard treatment and disclose use: Adding rather than substituting ivermectin, and telling the oncologist, avoids the survival loss linked to refusing standard care and enables interaction checks.
  • Parasite screening: Threadworm blood testing before immune-suppressing treatment, and a daytime Loa loa blood smear for anyone who lived in Central or West Africa, prevent hyperinfection and encephalopathy.

Therapeutic Protocol

  • Continuous integrative regimen (Paul Marik, Independent Medical Alliance): 0.2–0.4 mg/kg daily, usually starting at 0.3 mg/kg, titrated to a 0.8–1.0 mg/kg ceiling on progression (Marik, 2026). The alliance’s network clinicians earn consultation fees from these protocols.
  • Pulse dosing (integrative practitioners, summarized by Paul Marik): 0.4 mg/kg daily for 5 days every 2–4 weeks, or 0.3–0.6 mg/kg three times weekly, mainly after remission to limit cumulative exposure (Marik, 2026).
  • Trial regimen with immunotherapy (Cedars-Sinai): 30, 45 or 60 mg on days 1–3 of each week plus balstilimab every 3 weeks (NCT05318469); co-sponsored by balstilimab’s manufacturer.
  • Randomized dose comparison (University of Florida): 200 versus 400 µg/kg on days 1–3 weekly for 4 weeks alongside standard checkpoint inhibitors (NCT07487805).
  • Telemedicine combination capsule: Compounded 25 mg ivermectin with 250 mg mebendazole, adjusted by dose tier, in the McCullough Foundation cohort (Hulscher et al., 2026).
  • Conventional oncology position: The FDA discourages cancer use outside clinical trials, as noted in a 2026 case report; the American Society of Clinical Oncology, whose members earn income from conventional treatment, finds no support (What to Know About Ivermectin).
  • Time of day: No study compares timing; morning dosing with a consistent meal lets dizziness or visual symptoms be noticed while awake.
  • Half-life and food: Plasma half-life is about 18 hours and a fatty meal raises exposure 2.6-fold (Guzzo et al., 2002), so taking it the same way daily keeps levels stable.
  • Single versus split doses: Once daily suits the half-life; near 1 mg/kg, Marik splits the dose into 0.5 mg/kg twice daily to reduce side effects (Marik, 2026).
  • Genetic variants: Known ABCB1 or CYP3A4/CYP3A5 variants justify a lower starting dose; routine genotyping is not part of any published protocol.
  • Sex: No sex-based dosing differences are reported; all regimens are weight-based, which matters for smaller patients using fixed-strength capsules.
  • Age: Older adults usually start at the low end because of polypharmacy (several concurrent medications) and slower drug clearance.
  • Baseline biomarkers: Normal liver tests and adequate blood counts are trial entry requirements; no biomarker predicts response.
  • Pre-existing conditions: Liver disease, epilepsy or brain metastases prompt lower doses or avoidance; threadworm infection calls for standard 200 µg/kg antiparasitic treatment regardless of cancer goals.

Discontinuation & Cycling

  • Short-term or lifelong: Integrative regimens run open-ended while disease is controlled; trials continue until progression, toxicity or 2 years. No data support lifelong use or define an optimal duration.
  • Withdrawal effects: None known; ivermectin causes no dependence or rebound.
  • Tapering: Not required; stopping abruptly is standard, including when neurotoxicity appears.
  • Cycling: Pulse schedules aim to limit cumulative exposure, while Marik keeps ivermectin continuous and rotates other drugs every 4 weeks (Marik, 2026); neither approach has comparative data on efficacy.
  • Stop triggers: Neurological symptoms, ALT above 3 times the upper limit, blistering rash, or progression on imaging.
  • Before interacting drugs: Pausing ivermectin 3–4 days (about four half-lives) before starting a strong CYP3A4 or P-glycoprotein inhibitor avoids overlapping exposure.

Sourcing and Quality

  • Prescription tablets: Brand Stromectol (Merck) and generic 3 mg tablets (e.g., Edenbridge Pharmaceuticals) are made under FDA manufacturing standards, giving predictable content per tablet.
  • Compounded capsules: State-licensed compounding pharmacies prepare higher-strength capsules (e.g., 12–25 mg); a certificate of analysis showing potency and purity for each batch distinguishes reliable suppliers.
  • Veterinary products: Pastes, drenches and injectables for animals differ in concentration and inactive ingredients and account for most documented overdoses; they are not formulated for people.
  • Online and overseas sellers: Counterfeit or mislabeled tablets are common; checking the pharmacy’s license with the state board of pharmacy reduces this risk.
  • Third-party testing: Unlike supplements, approved tablets need no third-party seal; for compounded products, independent laboratory potency testing is the relevant check.
  • Access without prescription: Where state law allows it, pharmacy-sold ivermectin equals prescription quality, but no clinician reviews dose or interactions.
  • Storage: Below 30 °C, protected from light and moisture.

Practical Considerations

  • Time to effect: Trials judge response on imaging every 6–12 weeks; in the combination trial, median progression-free survival was 2.5 months (Yuan et al., 2025), so any benefit would be expected within 2–3 months.
  • Common pitfalls: Using veterinary products, escalating doses rapidly, stopping standard treatment, not telling the oncologist, stacking pump-inhibiting supplements, and crediting ivermectin for responses produced by concurrent chemotherapy.
  • Regulatory status: FDA-approved for strongyloidiasis and onchocerciasis; cancer use is off-label (outside approved indications) and unendorsed; several states allow sale without prescription.
  • Cost and access: Generic 3 mg tablets cost roughly $1–3 each in the US; daily weight-based cancer doses can reach several hundred dollars monthly and are rarely insured for this use.
  • Funding and payer incentives: Ivermectin is off-patent, so no manufacturer has reason to fund large cancer trials; insurers would gain from a cheap effective drug, so the structural bias lies in research funding rather than payer preference.

Interaction with Foundational Habits

  • Sleep: Indirect. Rising brain levels enhance calming signals and can cause drowsiness or dizziness; no study has measured sleep quality. Morning dosing and avoiding sedating sleep aids at higher doses reduce overlap; new daytime sleepiness signals a dose review.
  • Nutrition: Potentiating. Fatty meals raise absorption 2.6-fold, so high-fat or ketogenic (very low-carbohydrate, high-fat) diets common in metabolic cancer programs increase exposure; alcohol and grapefruit may raise levels. No nutrient depletion is known. Consistent meal timing relative to dosing keeps levels predictable.
  • Exercise: None known. No effect on muscle adaptation or endurance has been reported; at higher doses, dizziness or unsteadiness warrants caution with balance-demanding activities. Exercise itself remains independently useful during cancer care.
  • Stress management: None known. No effect on cortisol or stress response has been studied; brain exposure at ordinary doses is minimal. Deciding among uncertain options can itself add stress, which shared decisions with the oncology team may ease.

Monitoring Protocol & Defining Success

Baseline testing before starting ivermectin establishes liver, kidney and blood-count values, documents tumor burden with imaging and tumor markers, and screens for threadworm or Loa loa infection in anyone with relevant residence history. The full medication and supplement list is checked for CYP3A4 and P-glycoprotein interactions at the same visit.

Ongoing monitoring follows a cadence of liver tests and blood counts at 2 and 4 weeks, then every 2–3 months; INR 3–7 days after any dose change for warfarin users; and tumor markers with imaging every 8–12 weeks, the interval used in oncology trials. Success means stable or shrinking disease on imaging with maintained daily function and no neurological or liver toxicity; symptom improvement alone does not establish tumor control.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 10–26 U/L Detects liver injury Conventional upper limit about 40–55 U/L; above 3 times the upper limit is the usual stop threshold; morning fasting sample is standard, paired with AST (aspartate aminotransferase, a liver and muscle enzyme)
AST 10–26 U/L Confirms liver injury pattern Conventional upper limit about 40 U/L; also rises after hard exercise, so no strenuous training in the 48 hours before testing gives a cleaner reading
Total bilirubin 0.3–1.0 mg/dL Shows impaired liver clearance Conventional upper limit 1.2 mg/dL; Gilbert syndrome (a harmless inherited trait) raises it; fasting sample
CBC White cells 5.0–8.0 ×10⁹/L; platelets 150–350 ×10⁹/L Tracks marrow reserve CBC = complete blood count; conventional white-cell range 4.0–11.0 ×10⁹/L; ivermectin occasionally lowers white cells; interpret alongside chemotherapy timing
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Guides dosing of co-medications eGFR = estimated glomerular filtration rate (kidney filtering capacity); conventional threshold above 60; a high-protein meal before sampling can raise creatinine
INR (warfarin users only) Individual target, usually 2.0–3.0 Detects interaction-driven bleeding risk Checked 3–7 days after starting or changing ivermectin, at the same time of day as usual checks
Tumor markers (CEA, CA 15-3, CA-125, PSA) No established target; track change from own baseline Early signal of response or progression CEA = carcinoembryonic antigen; CA 15-3 and CA-125 = cancer antigens for breast and ovarian cancer; PSA = prostate-specific antigen; results are comparable only within the same laboratory
Imaging (CT, MRI or PET) No functional target; stable or shrinking lesions versus baseline Defines tumor control CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emission tomography; every 8–12 weeks, same modality each time
Strongyloides serology Negative Excludes hidden threadworm infection Once at baseline for people from tropical or subtropical regions, or before corticosteroids
Loa loa blood smear 0 microfilariae/mL (must be below 8,000) Excludes encephalopathy risk Daytime sample (10 am–2 pm) when larvae circulate; only after residence in West or Central Africa

Qualitative markers track early toxicity and whether daily life is improving:

  • Vision: Blurred vision or altered color perception, the earliest dose-limiting sign
  • Balance and coordination: New unsteadiness, tremor or falls
  • Alertness and memory: Drowsiness, confusion or slowed thinking
  • Energy and appetite: Changes relative to the pre-treatment baseline
  • Digestive tolerance: Nausea, diarrhea or abdominal pain
  • Cancer symptoms and function: Pain, breathlessness and ability to carry out daily activities

Emerging Research

  • Ivermectin with checkpoint antibodies in triple-negative breast cancer: Early-phase (I/II) trial at Cedars-Sinai (NCT05318469) adding ivermectin to antibodies against PD-1 (an immune-brake receptor), 34 planned participants; primary endpoints adverse events and response rate. Interim data showed 1 response in 8 (Yuan et al., 2025); completion expected October 2026.
  • ICONIC randomized dose comparison: Phase II trial at the University of Florida (NCT07487805) randomizing 80 people on checkpoint inhibitors to 200 or 400 µg/kg; primary endpoint change in proliferating CD8 T cells (cancer-killing immune cells) at 2 weeks, with severe adverse-event and blood cytokine (immune signaling protein) measures. Not yet recruiting.
  • Achievable concentration debate: Effects at 5 µM across 28 cell lines support trials (Juarez et al., 2020), whereas cell killing disappeared once drug precipitates were filtered (Qabbus et al., 2022). Measuring ivermectin in patients’ tumor tissue could decide which reading holds.
  • Integrity of key preclinical studies: A 2026 expression of concern on the main immune-activation mouse study and a 2026 retraction notice for a liver cancer synergy study weaken the laboratory rationale until independent replication appears.
  • Real-world cohorts: Self-reported benefit in 197 telemedicine patients (Hulscher et al., 2026) is hypothesis-generating; registries with imaging-confirmed outcomes and comparison groups could strengthen or weaken the case.
  • Long-term high-dose safety: Oncology case reports of neurotoxicity and liver injury (Saperstein et al., 2026; Powderly et al., 2026) and sparse high-dose trial data (Navarro et al., 2020) leave months-long dosing uncharacterized.

Conclusion

Ivermectin is a cheap, long-established drug for parasitic worms that many people with cancer now take, alone or through doctors who repurpose older drugs. The case for it rests on a large, consistent body of laboratory and animal research showing that it can slow or kill cancer cells through several growth signals, help the immune system find tumors, and make some cancers more sensitive to chemotherapy. The human evidence is far thinner: one small early trial in advanced breast cancer, a group study relying on patients’ own reports, and scattered cases. None compared users with similar people not taking the drug, so none shows whether it controls tumors or extends life.

The main risks are brain and nerve side effects when doses climb or other medicines slow its removal from the body, rare liver and skin injury, interactions with some cancer drugs and blood thinners, and, most consequential, using it in place of treatments known to work. Ordinary doses are well tolerated, but the higher, months-long doses used for cancer have little safety data.

Interests shape evidence on both sides: cancer specialist societies whose members earn income from standard care, practitioner networks and online prescribing businesses that earn income from these protocols, and a partner-drug maker funding the main trial. One key animal study now carries a formal warning about its data. For people with cancer, the evidence shows laboratory promise, real but manageable risks, and an effect on survival that remains unknown.

Top - Benefits - Risks - Protocol